soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Canadian Perspectives 2025 Whiteboard on the Semaglutide and Cardiovascular Outcomes in

Your body does produce more GLP-1 during fasting periodsresearch shows a 2030% elevation in some studiesbut this natural boost falls far short of therapeutic levels needed for sustained appetite suppression and metabolic change

Youve got nothing to lose but the weight!

Clinical insight: Patients who start anti-nausea meds in week 1 report 40% less severe nausea during peak weeks 6-8 compared to those who wait until symptoms are intolerable

Health systems should move beyond isolated pilots and prioritise enterprise-ready AI tools that reduce administrative workload, integrate with EHR systems, and show measurable clinical or operational outcomes

Users essentially participate in uncontrolled experimentation when using BPC-157, a reality that deserves frank acknowledgment